Teva Pharmaceuticals, an American subsidiary of Teva Pharmaceutical Industries (TEVA), has announced the release of the first and only generic version of Sandostatin LAR Depot in the United States. This generic version, known as octreotide acetate for injectable suspension, is approved for the treatment of acromegaly and severe diarrhea associated with carcinoid syndrome.
"With today's launch of octreotide acetate for injectable suspension, Teva is providing patients a new option for this important treatment," said Ernie Richardsen, Senior Vice President of U.S. Commercial Generics.
The company highlighted that annual sales of Sandostatin LAR Depot reached $826 million as of July 2024.